Caricamento...
Introducing Vernakalant into Clinical Practice
Vernakalant is an antiarrhythmic drug licensed for the pharmacological cardioversion of recent onset AF. Randomised clinical trials, backed up by real-world experience, have confirmed its efficacy at restoring sinus rhythm. Vernakalant can be administered simply with a short time to action, facilita...
Salvato in:
| Pubblicato in: | Arrhythm Electrophysiol Rev |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Radcliffe Cardiology
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6434499/ https://ncbi.nlm.nih.gov/pubmed/30918671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/aer.2018.71.2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|